GGB:
You make a very valid point to which I have alluded in previous posts.
Candidly, I believe that big P and other experts, real and so-called, think that DCVaxL works. The real question is not whether it works but how well.
As an investor, even assuming that the results are stellar at top line announcement and all endpoints are comfortably achieved with milestone/long tail home runs covering a broad spectrum of GBM cancers, i.e., M+ and MES for example or about 60% of ndGBM, would the price rise significantly and be sustainable in face of nefarious forces keeping a lid on any rise and then walking the price down again casting doubts upon commercialization challenges, dilutive financings, etc. Would investors need to wait months if not a year for reg approvals after top line announcements? How powerful are these forces? Is it a question where, as a practical matter, you just can't fight nefarious "city hall"? I must admit that I don't know the answer to that. We have seen how well these forces conspire to keep the lid on when good news issues. The data published in the JTM was excellent as were the updates at SNO. We are close to the finish line but the stock price languishes and there is not enough momentum to keep the upward spike going for long. FUD and manipulation continue rampantly and unchecked. CI darlings not even in phase III are bought out at billion dollar valuations but NWBO can't sustain itself at $300 million.
However, just imagine market reaction and what the manipulators/shorts will do if the primary/secondary endpoints are not met. The focus will be that the trial failed; that this failure is attempted to be salvaged by appeal to other criteria; and, hence approval is still highly risky and will not issue anytime soon if at all. The stock continues to languish at current levels and well below a dollar. Any reverse split to get uplifted to NASDAQ, etc. will be met by furious shorting, thus nullifying the reason for the R/S in the first place. Back to square one and rinse,repeat. Financing will be required with once again deep discounts and warrant incentives.
Thus, it is critically important for the primary and secondary endpoints to be met, not necessarily for RA approvals, although that would be helpful, for share price appreciation
and sustainability. If these endpoints are not met, investors had better plan for a very long term ROI. JMHO.
